1059 related articles for article (PubMed ID: 25445928)
1. Differences in the efficacy and safety among inhaled corticosteroids (ICS)/long-acting beta2-agonists (LABA) combinations in the treatment of chronic obstructive pulmonary disease (COPD): Role of ICS.
Latorre M; Novelli F; Vagaggini B; Braido F; Papi A; Sanduzzi A; Santus P; Scichilone N; Paggiaro P
Pulm Pharmacol Ther; 2015 Feb; 30():44-50. PubMed ID: 25445928
[TBL] [Abstract][Full Text] [Related]
2. Inhaled steroids and risk of pneumonia for chronic obstructive pulmonary disease.
Kew KM; Seniukovich A
Cochrane Database Syst Rev; 2014 Mar; 2014(3):CD010115. PubMed ID: 24615270
[TBL] [Abstract][Full Text] [Related]
3. Long-acting inhaled therapy (beta-agonists, anticholinergics and steroids) for COPD: a network meta-analysis.
Kew KM; Dias S; Cates CJ
Cochrane Database Syst Rev; 2014 Mar; 2014(3):CD010844. PubMed ID: 24671923
[TBL] [Abstract][Full Text] [Related]
4. Combination of budesonide/formoterol more effective than fluticasone/salmeterol in preventing exacerbations in chronic obstructive pulmonary disease: the PATHOS study.
Larsson K; Janson C; Lisspers K; Jørgensen L; Stratelis G; Telg G; Ställberg B; Johansson G
J Intern Med; 2013 Jun; 273(6):584-94. PubMed ID: 23495860
[TBL] [Abstract][Full Text] [Related]
5. Comparing a fixed combination of budesonide/formoterol with other inhaled corticosteroid plus long-acting beta-agonist combinations in patients with chronic obstructive pulmonary disease: a review.
Solidoro P; Patrucco F; Bagnasco D
Expert Rev Respir Med; 2019 Nov; 13(11):1087-1094. PubMed ID: 31498714
[No Abstract] [Full Text] [Related]
6. Severe exacerbation and pneumonia in COPD patients treated with fixed combinations of inhaled corticosteroid and long-acting beta2 agonist.
Yang HH; Lai CC; Wang YH; Yang WC; Wang CY; Wang HC; Chen L; Yu CJ
Int J Chron Obstruct Pulmon Dis; 2017; 12():2477-2485. PubMed ID: 28860742
[TBL] [Abstract][Full Text] [Related]
7. Comparative Effectiveness and Safety of Different Types of Inhaled Long-Acting β
Wang MT; Lai JH; Huang YL; Liou JT; Cheng SH; Lin CW; Pan HY; Hsu YJ; Tsai CL
Chest; 2021 Oct; 160(4):1255-1270. PubMed ID: 34023320
[TBL] [Abstract][Full Text] [Related]
8. Comparative analysis of budesonide/formoterol and fluticasone/salmeterol combinations in COPD patients: findings from a real-world analysis in an Italian setting.
Perrone V; Sangiorgi D; Buda S; Degli Esposti L
Int J Chron Obstruct Pulmon Dis; 2016; 11():2749-2755. PubMed ID: 27853362
[TBL] [Abstract][Full Text] [Related]
9. Inhaled corticosteroids versus long-acting beta(2)-agonists for chronic obstructive pulmonary disease.
Spencer S; Evans DJ; Karner C; Cates CJ
Cochrane Database Syst Rev; 2011 Oct; (10):CD007033. PubMed ID: 21975759
[TBL] [Abstract][Full Text] [Related]
10. Combined corticosteroid and long-acting beta(2)-agonist in one inhaler versus inhaled corticosteroids alone for chronic obstructive pulmonary disease.
Nannini LJ; Poole P; Milan SJ; Kesterton A
Cochrane Database Syst Rev; 2013 Aug; 2013(8):CD006826. PubMed ID: 23990350
[TBL] [Abstract][Full Text] [Related]
11. The impact of inhaled corticosteroid and long-acting beta-agonist combination therapy on outcomes in COPD.
Hanania NA
Pulm Pharmacol Ther; 2008; 21(3):540-50. PubMed ID: 18280761
[TBL] [Abstract][Full Text] [Related]
12. Inhaled corticosteroids versus long-acting beta(2)-agonists for chronic obstructive pulmonary disease.
Spencer S; Karner C; Cates CJ; Evans DJ
Cochrane Database Syst Rev; 2011 Dec; 2011(12):CD007033. PubMed ID: 22161409
[TBL] [Abstract][Full Text] [Related]
13. Budesonide/Glycopyrronium/Formoterol: A Review in COPD.
Heo YA
Drugs; 2021 Aug; 81(12):1411-1422. PubMed ID: 34342835
[TBL] [Abstract][Full Text] [Related]
14. Effects of inhaled corticosteroids /long-acting agonists in a single inhaler versus inhaled corticosteroids alone on all-cause mortality, pneumonia, and fracture in chronic obstructive pulmonary disease: A nationwide cohort study 2002-2013.
Cho KH; Kim YS; Linton JA; Nam CM; Choi Y; Park EC
Respir Med; 2017 Sep; 130():75-84. PubMed ID: 29206637
[TBL] [Abstract][Full Text] [Related]
15. Comparative Safety and Effectiveness of Inhaled Corticosteroid and Long-Acting β
Chang TY; Chien JY; Wu CH; Dong YH; Lin FJ
Chest; 2020 May; 157(5):1117-1129. PubMed ID: 31887282
[TBL] [Abstract][Full Text] [Related]
16. Effects of roflumilast in COPD patients receiving inhaled corticosteroid/long-acting β2-agonist fixed-dose combination: RE(2)SPOND rationale and study design.
Rennard SI; Martinez FJ; Rabe KF; Sethi S; Pizzichini E; McIvor A; Siddiqui S; Anzueto A; Zhu H
Int J Chron Obstruct Pulmon Dis; 2016; 11():1921-8. PubMed ID: 27574416
[TBL] [Abstract][Full Text] [Related]
17. Combined corticosteroid and long-acting beta₂-agonist in one inhaler versus placebo for chronic obstructive pulmonary disease.
Nannini LJ; Poole P; Milan SJ; Holmes R; Normansell R
Cochrane Database Syst Rev; 2013 Nov; 2013(11):CD003794. PubMed ID: 24214176
[TBL] [Abstract][Full Text] [Related]
18. The use of long acting β₂-agonists, alone or in combination with inhaled corticosteroids, in chronic obstructive pulmonary disease (COPD): a risk-benefit analysis.
Cave AC; Hurst MM
Pharmacol Ther; 2011 May; 130(2):114-43. PubMed ID: 21276815
[TBL] [Abstract][Full Text] [Related]
19. LABA/LAMA versus LABA/ICS fixed-dose combinations in the prevention of COPD exacerbations: a modeling analysis of literature aggregate data.
Gong Y; Sui Z; Lv Y; Zheng Q; Li L
Eur J Clin Pharmacol; 2023 Oct; 79(10):1321-1332. PubMed ID: 37507595
[TBL] [Abstract][Full Text] [Related]
20. The bioavailability and airway clearance of the steroid component of budesonide/formoterol and salmeterol/fluticasone after inhaled administration in patients with COPD and healthy subjects: a randomized controlled trial.
Dalby C; Polanowski T; Larsson T; Borgström L; Edsbäcker S; Harrison TW
Respir Res; 2009 Oct; 10(1):104. PubMed ID: 19878590
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
